Rejuvenated induced pluripotent stem cells (iPSCs) for use in autologous regenerative therapy in an adult human subject that is more than 50 years old, wherein said rejuvenated iPSCs are obtained by a method comprising the steps of: a) providing a cell composition obtained from said adult human subject that is at least 50 years old, and, b) culturing said cell composition under appropriate conditions for reprogramming said cell composition into human rejuvenated iPSCs, wherein said appropriate conditions comprise increasing expression in said cell composition of at least the following combination of reprogramming factors: i. Oct4, ii. Klf4, iii. Sox2, iv. C-Myc, v. Lin28, vi. and Nanog, thereby obtaining said human rejuvenated iPSC cells, wherein said method does not comprise a step of silencing senescence effectors in said cell composition, such as p21 CIP and/or p16 INK4a and/or p53, wherein one or all of the following phenotype is suppressed in the rejuvenated induced pluripotent stem cells: - activation of p16 INK4A or p21 CIP senescence effectors, - cells arrested irreversibly in G1, - shortening of telomerase size, - expression of senescent-associated beta-galactosidase activity, - specific chromatin modification as senescence-associated heterochromatic foci, wherein said rejuvenated iPSCs are obtained by a method comprising the steps of: a) providing a cell composition obtained from said adult human subject that is at least 50 years old, and, b) culturing said cell composition under appropriate conditions for reprogramming said cell composition into human rejuvenated iPSCs, wherein said appropriate conditions comprise increasing expression in said cell composition of at least the following combination of reprogramming factors: i. Oct4, ii. Klf4, iii. Sox2, iv. C-Myc, v. Lin28, vi. and Nanog, thereby obtaining said human rejuvenated iPSC cells, wherein said method does not comprise a step of silencing senescence effectors in said cell composition, such as p21 CIP and/or p16 INK4a and/or p53, a) providing a cell composition obtained from said adult human subject that is at least 50 years old, and, b) culturing said cell composition under appropriate conditions for reprogramming said cell composition into human rejuvenated iPSCs, wherein said appropriate conditions comprise increasing expression in said cell composition of at least the following combination of reprogramming factors: i. Oct4, ii. Klf4, iii. Sox2, iv. C-Myc, v. Lin28, vi. and Nanog, thereby obtaining said human rejuvenated iPSC cells, i. Oct4, ii. Klf4, iii. Sox2, iv. C-Myc, v. Lin28, vi. and Nanog, wherein one or all of the following phenotype is suppressed in the rejuvenated induced pluripotent stem cells: - activation of p16 INK4A or p21 CIP senescence effectors, - cells arrested irreversibly in G1, - shortening of telomerase size, - expression of senescent-associated beta-galactosidase activity, - specific chromatin modification as senescence-associated heterochromatic foci, - activation of p16 INK4A or p21 CIP senescence effectors, - cells arrested irreversibly in G1, - shortening of telomerase size, - expression of senescent-associated beta-galactosidase activity, - specific chromatin modification as senescence-associated heterochromatic foci,